StockNews.com Begins Coverage on DBV Technologies (NASDAQ:DBVT)

Research analysts at StockNews.com initiated coverage on shares of DBV Technologies (NASDAQ:DBVT) in a note issued to investors on Monday. The firm set a “hold” rating on the stock.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of DBV Technologies in a research report on Wednesday, February 21st.

DBV Technologies Stock Performance

Shares of DBVT opened at $0.67 on Monday. The company has a 50-day simple moving average of $0.76 and a 200-day simple moving average of $0.85. DBV Technologies has a 52 week low of $0.65 and a 52 week high of $2.37. The firm has a market capitalization of $128.63 million, a P/E ratio of -1.71 and a beta of 0.73.

DBV Technologies (NASDAQ:DBVT) last issued its quarterly earnings results on Thursday, March 7th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.10. DBV Technologies had a negative return on equity of 46.33% and a negative net margin of 461.32%. The firm had revenue of $8.88 million for the quarter, compared to analyst estimates of $1.10 million. During the same period in the previous year, the company posted ($0.23) earnings per share. As a group, equities analysts forecast that DBV Technologies will post -0.88 earnings per share for the current year.

Hedge Funds Weigh In On DBV Technologies

A number of hedge funds have recently modified their holdings of the stock. Cowen AND Company LLC acquired a new stake in DBV Technologies in the 4th quarter valued at $49,000. Landscape Capital Management L.L.C. bought a new position in shares of DBV Technologies during the third quarter valued at $94,000. Finally, Optiver Holding B.V. lifted its holdings in shares of DBV Technologies by 595.2% during the third quarter. Optiver Holding B.V. now owns 274,874 shares of the company’s stock valued at $374,000 after acquiring an additional 235,337 shares during the period. 71.74% of the stock is owned by institutional investors and hedge funds.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.